Core Viewpoint - The Broadmark Realty Capital Inc. class action lawsuit alleges violations of the Securities Exchange Act of 1934 related to the merger with Ready Capital Corporation, with claims of misleading statements and undisclosed financial distress among borrowers [1][3]. Group 1: Class Action Lawsuit Details - Holders of Broadmark common stock as of the May 2023 merger record date can seek lead plaintiff status until July 28, 2025 [1][2]. - The lawsuit is titled Grant v. Broadmark Realty Capital, No. 25-cv-01013 (W.D. Wash.) and involves Broadmark, Ready Capital, and certain executives and directors [1][2]. - The proxy statement for the merger allegedly contained false or misleading information regarding financial conditions and projections [3]. Group 2: Allegations Against Broadmark and Ready Capital - A significant portion of Ready Capital's borrowers faced financial distress due to high interest rates, impacting their ability to cover debt costs [3]. - An oversupply of multifamily properties limited rent increases necessary for borrowers to manage growing debt [3]. - A major development project acquired during the merger faced severe setbacks, including cost overruns and funding shortfalls, affecting approximately $500 million of Ready Capital's loan portfolio [3]. - Ready Capital's expected credit loss reserves were allegedly understated, leading to unrealistic financial projections [3]. Group 3: Legal Representation and Firm Background - The plaintiff is represented by Robbins Geller, a law firm with extensive experience in prosecuting investor class actions [4]. - Robbins Geller has secured over $2.5 billion for investors in securities-related class action cases in 2024, ranking first in monetary relief for investors [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Red Cat Holdings, Inc. securities between March 18, 2022, and January 15, 2025, of the July 22, 2025, deadline to become a lead plaintiff in a class action lawsuit due to alleged misleading statements by the company [1][4]. Group 1: Class Action Details - Investors who purchased Red Cat securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by July 22, 2025, to serve as lead plaintiff [2]. - The lawsuit claims that Red Cat made false and misleading statements regarding its production capacity and the value of its contracts, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - Jasper Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in stock price due to issues related to a drug product lot in a clinical study [1][2]. Group 1: Company Overview - Jasper Therapeutics, Inc. is publicly traded on NASDAQ under the ticker symbol JSPR [1]. - The company recently reported updated data from its BEACON Phase 1b/2a study of briquilimab, which is intended for adult participants with chronic spontaneous urticaria (CSU) [2]. Group 2: Recent Developments - On July 7, 2025, Jasper announced that results from certain dose cohorts of its clinical study were confounded by issues with a specific drug product lot, affecting 10 out of 13 patients in those cohorts [2]. - Following this announcement, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of Jasper investors, focusing on potential securities fraud and misconduct by the company and its officers or directors [1]. - The Pomerantz Firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3].

NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brown-Forman Corporation ("Brown-Forman" or the "Company") (NYSE: BF-B; BF-A). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Brown-Forman and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On J ...

Core Viewpoint - Abacus Global Management, Inc. is under investigation for potential securities fraud and unlawful business practices, following allegations of manipulating financial reporting to appear more profitable than it is [1][2]. Group 1: Investigation and Allegations - An investigation is being conducted on behalf of investors of Abacus Global Management regarding possible securities fraud by the company and its officers or directors [1]. - A report by Morpheus Research claims that Abacus has altered its portfolio valuation methodology to inflate profitability and uses questionable life expectancy calculations, raising concerns about the integrity of its financial practices [2]. Group 2: Market Reaction - Following the news of the investigation and the allegations, Abacus's stock price experienced a significant decline, falling by $1.64 per share, or 21.47%, closing at $6.00 per share on June 5, 2025 [3].

NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Funko, Inc. ("Funko" or the "Company") (NASDAQ: FNKO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Funko and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 7, 2025, Funko announced ...

NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Broadmark Realty Capital Inc. ("Broadmark" or the "Company") (NYSE: BRMK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Broadmark and certain of ...

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company [2] - The company has not yet appointed a successor for the CFO position, creating uncertainty as it faces market and legal challenges [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of the company's full-year revenue projections [3][6] - The first-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a class-action securities fraud lawsuit related to its claims about authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5] - The lawsuit alleges discrepancies between the company's public statements about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7]

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, which is administered at authorized treatment centers (ATCs) [3]. Group 2: Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Group 3: Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].